The purpose of the study was to examine the influence of age on outcome in a large cohort of children and adults with lymphoblastic leukaemia who were treated on two similar trials. Factors influencing outcome were examined in 2204 patients aged over 1 year treated between 1985 and 1992 on the parallel Medical Research Council Trials UKALL X and Xa, for children and adults, respectively. There was a progressive worsening in survival with increasing age from 85% (95% CI 83-87) at 5 years for children aged 1-9 to 24% (CI 17-31) for patients over 40. Induction failures, deaths in remission and bone marrow relapses increased significantly with age. Analysis of clinical and biological features showed dominance of early B-ALL in childhood and increasing incidence of the PhЈ chromosome with age. Over 80% of eligible children, but a much lower proportion of adults especially those over 40, was entered. Compliance was stricter in the paediatric trial but most deviations in adults involved giving more treatment. Analysis of results in a proportional hazards model confirmed the overwhelming independent influence of age; with all other factors equal a 10 year old had half the risk of treatment failure of a 20 year old and a 44 year old double the risk. Selective entry to therapeutic trials and increased treatment-related toxicity are features of adult ALL but age itself remains a dominant prognostic factor. While improved supportive care and refinements of conventional therapy may have some effect on prognosis, new understandings and treatment approaches to adult ALL are needed.
Introduction
Progress in the treatment of children with acute lymphoblastic leukaemia (ALL) has not been accompanied by a parallel improvement in outcome for adults, even when both are treated with similar regimens.
1,2 Some clear differences explain this discrepancy in part. These include biological factors such as different distributions amongst the immunologically defined subtypes of ALL and genetic features. Declining treatment tolerance and compliance with increasing age may provide some explanation for these differences but cannot account for the major impact of age.
The recent MRC UKALL X and XA trials, which used similar treatment regimens and were open to both children and adults with acute lymphoblastic leukaemia, offer a unique opportunity to examine these conventional prognostic variables and we present here an analysis of the presently recognised clinical and biological prognostic factors and their influence on outcome; the main conclusions of the randomised treatment comparisons are reported elsewhere. 3, 4 This study demonstrates that, once infants are excluded, there is an overwhelming effect of increasing age on outcome across the entire age span.
MRC UKALL X succeeded MRC UKALL VIII, which has been previously reported, 5 and the basic treatment schedule was derived from this trial. It was open to all children in the UK and Ireland aged up to 14 years of age excluding only the 1-2% with surface membrane immunoglobulin positive B-ALL. The trial opened in January 1985 and closed in September 1990. All patients have been followed up until October 1996, a maximum of 11. and a minimum of 6 years from diagnosis.
MRC UKALL XA succeeded MRC UKALL IX which has been previously reported 6 and was open to all adults aged 15 and over in the UK, except those with B-ALL. It ran from April 1985 to December 1992 and all patients have been followed up until October 1996, a maximum of 11. and a minimum of 32 years from diagnosis.
The basic treatment schema for both trials is shown in Figure 1 . All children aged 0-14 years, except those with CNS disease at presentation, with an initial leukocyte count of greater than 100 × 10 9 /l, or, initially good risk girls (see below), were randomised with respect to early and late intensification, given at 5 and 20 weeks from diagnosis. The timing of the intensification blocks and the difference between protocol arms is shown in Figure 2 . The composition of the two additional intensification blocks, which were identical, is shown in Figure 1 . Continuing (maintenance) chemotherapy with daily mercaptopurine and weekly oral methotrexate adjusted to tolerance together with monthly prednisolone and vincristine was given until 2 years from the achievement of remission. Co-trimoxazole was given by mouth on 3 days each week for prophylaxis of Pneumocystis carinii pneumonia.
All children received central nervous system-directed therapy with a course of three intrathecal methotrexate injections during the induction phase in a dose based on age, 7 one additional injection during intensification blocks, if these were given, and three further injections during and after cranial irradiation. All children received cranial irradiation in a dose of 18 Gy in 10 fractions over 2 weeks between weeks 6 and 12 dependent on the treatment allocated; this was delayed in children under 2 years of age at the time of diagnosis, who received a course of intrathecal methotrexate injections at the time scheduled and then intrathecal methotrexate every 4 weeks for four doses and then every 8 weeks until after the second birthday when cranial irradiation was given.
Children with CNS disease at diagnosis, defined as the presence of more than five cells per mm 3 , which were recognizable blast cells, were not randomized and were electively given early intensification (regimen B) followed by radiotherapy in a dose of 24 Gy to the cranium and 12 Gy to the spine. Children with an initial leucocyte count of more than 100 × 10 9 /l were not randomised but were assigned to
Figure 1
The basic design of UKALL X and XA showing the timing and composition of intensification blocks.
Figure 2
The basic randomization schedule for both UKALL X and XA. All patients with the exception of those mentioned in the text were randomized to one of four treatment regimens: (A) no intensification; (B) early intensification; (C) late intensification; and (D) both early and late.
regimen D and 24 Gy of cranial irradiation while those with a histocompatible sibling donor were eligible to receive cyclophosphamide, total body irradiation and allogeneic bone marrow transplantation (BMT) in first remission. 8 For the first 3 years of the trial girls aged 2-9 years inclusive, with an initial leucocyte count of less than 20 × 10 9 /l were not randomized, but were allocated to regimen A (no intensification); subsequently they were all randomised.
The differences between the adult and the paediatric protocol were as follows. Only adult patients with an initial leucocyte count of less than 50 × 10 9 were eligible for randomization. Patients with an initial leucocyte count of over 50 × 10 9 /l were placed on schedule D or eligible for allogeneic BMT if they had an histocompatible sibling donor. All patients received CNS directed therapy with 24 Gy of cranial irradiation rather than 18 Gy. Routine co-trimoxazole was not initially recommended in the adult protocol, but this policy was reviewed and then revised after 1 year.
Immunophenotypic analyses
Immunophenotyping was performed for the most part at the treatment centres using a panel of monoclonal antibodies recommended in the protocol. The results were reviewed centrally and a number of workshops were held to assist in standardization of methodology. Despite this, investigation for the presence of cytoplasmic immunoglobulin was not routinely performed in most centres. The leukaemias were therefore classified as pre-pre-B (TdT+ve, HLA DR+ve, CD19+ve, CD10−ve), common or pre-B (CD10+ve, CD19+ve, HLA DR+ve, TdT+ve), T-ALL (CD19-ve, TdT+ve, CD2+ve, CD7+ve), or 'other'. There was no standardized protocol nor requirement for investigation with 'myeloid' antibodies.
Cytogenetic analyses
Cytogenetic analysis was performed at local centres (UKALL X) while 50% were performed locally in UKALL XA and 50% in a designated laboratory. The results presented here were coded according to ploidy group and the presence of established non-random abnormalities. 9 
Statistical methods
Since patients under the age of 1 year are known to have a different type of leukaemia, with adverse prognostic features, they have been excluded from the analyses presented here. It was anticipated that this might enable any linear or monotonic effect of age on prognosis to be investigated. Univariate association of presenting features with age groups and different types of first event were assessed by 2 tests for heterogeneity and trend. Fisher's exact test was used where numbers were very small. All continuous measures were initially analysed as ordinate variables. The Cochran-Mantel-Haenszel 2 statistic was used for stratified tests of association. Diseasefree survival (time to leukaemic relapse or death in complete remission) was calculated from entry, with non-remitters classified as having an event on day 1. Patients who received a bone marrow transplant, either BMT or autologous bone marrow transplant (ABMT) were censored at the time of transplant. Kaplan-Meier survival curves were constructed and differences between groups analysed by the log-rank test. 10 Multivariate analysis was performed using Cox's proportional hazards model.
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Results
Accrual of patients
The annual accrual of patients to each trial is shown in Table 1 together with the estimated annual incidence of ALL in each age group (the data have kindly been provided by the Leukaemia Research Fund Epidemiology Unit). Between 1985 and 1988 UKALL X was estimated to have accrued over 80% of children with ALL in the UK, both in the age group 1-9 and 10-14 years. The rate of entry fell in the last 2 years when two large centres were piloting the successor trial MRC UKALL XI and the number of infants fell because of development of a new infant protocol. Twenty-six infants under 1 year entered the trial but these have been excluded along with 23 others who were misdiagnosed, leaving 1586 children in total.
The highest proportion of entries to UKALL XA were in the 15-19 age group; among patients over 20 years of age, the number entered declined with increasing age. Twenty-one adults were excluded through misdiagnosis, leaving 618 available for analysis.
Protocol compliance
Compliance was good in the paediatric trial with major protocol deviations in 42 (2.5%) of cases. There was a difference between intensification protocol allocated and protocol given in only 29 of the randomized cases; in 26 the clinician did not deem it possible to give the additional intensification blocks because of treatment-related toxicity and three were electively given an additional intensification block. A total of 47 children were treated with chemoradiotherapy and bone marrow transplantation. Thirty-four received bone marrow transplantation in first remission according to protocol from a histocompatible sibling donor. An additional seven children who did not fulfil the criteria received a BMT in first remission, and six who were deemed at high risk for leukaemic relapse and did not have a sibling donor were treated by ABMT in first remission.
Compliance with the protocol in the adult trial was less satisfactory with 138 (22%) of patients deviating from protocol. Nine randomized patients did not receive an allocated treatment block because of treatment-related toxicity and 15 were given an additional intensification block to which they had not been allocated, and one allocated the late block, was given the early one instead. A total of 141 adults were treated with chemoradiotherapy and bone marrow transplantation. Twenty-eight with a leucocyte count of over 50 × 10 9 /l received an allogeneic transplant and an additional 30 ABMT in first remission. Among patients with initial leucocyte count under 50 × 10 9 /l, 44 were treated by BMT in first remission, one had an unrelated donor transplant and an additional 38 patients received an ABMT in first remission. Thus in the adult trial non-compliance usually involved the administration of more treatment than was determined by the randomization.
Clinical and biological features at presentation
The clinical and haematological features at presentation in the various age groups are shown in Table 2 . There was a pre- (25) 33 (17) 29 (14) 12 (7) 631 2 361 (27) 61 (26) 37 (19) 39 (18) 23 (13) 521 3 182 (14) 41 (18) 38 (20) 31 (15) 15 (8) Clinical and basic laboratory features at presentation. P values are for heterogeneity for sex, WBC and haemoglobin; all others are for trend. Grading system for enlargement of liver, spleen and lymph node: 0, not enlarged; 3, maximal.
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dominance of males in all age groups and some heterogeneity of leucocyte counts between age groups ( 2 = 32.2, P = 0.001), with more high counts in patients aged 10-39 years. Hepatomegaly, lymph node enlargement and splenomegaly all increased significantly with age (P Ͻ 0.0001 in each case). The distribution of immunophenotype reflects the significant predominance of c-ALL in childhood, the relatively higher incidence of T-ALL in the 10-39 year age group and the higher proportion of pre-pre-B ALL in the patients over 40 years of age. There was a strong inverse relationship between Hb level at presentation and age with significantly more young children presenting with Hb levels of less than 5 g/dl ( 2 = 194.7, P Ͻ 0.0001). The results of cytogenetic analysis are shown in Table 3 .
Slightly more samples were sent for cytogenetic analysis in the adult patients. There was a failure to obtain an interpretable result in 28% of all samples. A normal result was found in 38% of those samples in which a satisfactory analysis was obtained. There was a significant excess of high hyperdiploid (50-60 chromosomes) results in children aged 1-9 (trend 2 = 48.4, P Ͻ 0.0001) and significantly fewer children in this age group had pseudodiploidy (trend 2 = 51.3, P Ͻ 0.0001). The Table also shows the incidence of the major non-random cytogenetic abnormalities. The most significant finding was the increasing incidence of the PhЈ translocation with increasing age, rising from 1.3% in the 1-9 year age group to 19.2% in the patients over 40 (trend 2 = 76.6, P Ͻ 0.0001). The t(4;11) was found mainly in the over-40s while there was an even distribution of t(1;19). There was no relationship to age in the three other common abnormalities, del6q, abn9p and abn12p.
Response to treatment and disease-free survival Figure 3 shows disease-free survival in both trials by age and it can be seen that there is a progressive worsening in the prospect of disease-free survival from children aged 1-9 with 65% (95%, CI 62-67) at 5 years to 17% (95%, in the patients over 40. Similarly when survival is examined (Figure 4) , the results show 85% (95%, CI 83-87) at 5 years for children aged 1-9 and 23% (95%, CI 17-30) for patients over 40. There is a highly significant trend with age for both end points (log rank 2p Ͻ 0.0001). Table 4 shows the number of events (failure to remit, death in remission and relapse) according to age. All analyses have been stratified by gender, leucocyte count and treatment allocated and events after bone marrow transplant are excluded. The numbers and absolute percentage of those alive in remission at 5 years are shown. The results show a significant trend for increasing failure to remit, remission death and bone marrow relapse with increasing age. Figure 5 shows the remission duration by Kaplan-Meier analysis in the various age groups, with the over 40-year-old patients divided into those less and more than 60 years. There is no apparent difference in the absolute proportion of patients remaining in remission among the patients aged 15-19 and those aged 20-39, but the different ratios of observed to expected events indicate that relapses are earlier in the 20-39 year olds. The results show a highly significant trend for increasing relapse with age (2p Ͻ 0.00005).
Univariate and stratified analyses of factors influencing prognosis
The following variables were tested for univariate prognostic association with disease-free survival on the whole cohort of patients (n = 2204), censoring at the time of transplant for those receiving BMT or ABMT: age, WBC, gender, treatment given (whether no, one or two intensification blocks), immunophenotype (using each of T-ALL, C or pre-B, pre-pre-B as separate yes/no variables) lymph node involvement, enlargement of liver or spleen, haemoglobin, percentage blasts in
Figure 3
Disease-free survival by age in patients entered in UKALL X and XA. The starting point on the curve indicates remission rate. Patients under 1 year are excluded and all patients are censored at bone marrow transplant.
Figure 4
Survival by age in UKALL X and XA. Patients under 1 year are excluded and all patients are censored at bone marrow transplant.
bone marrow at diagnosis (BM blasts), involvement of the CNS at diagnosis and CSF blast count. The results are shown in Table 5 . In univariate analysis all these factors except CNS involvement, CSF blast cells and enlargement of liver or spleen were significant at the 5% level (log-rank test). Since, after age, leucocyte count and gender are the two most important independent prognostic factors, a further log-rank analysis stratified by WBC and gender was performed. Treatment became non-significant, whilst enlargement of liver and lymph node involvement became significant. The series of analyses was then repeated in the subset of patients for whom all variables including cytogenetic results were available (n = 1160) with the addition of variables to represent the various ploidy groups and the common structural abnormalities listed in Table 3 . T(4;11) and t(9;22) were significant; other non-random abnormalities were not significant. Response to treatment by age group. All P values are stratified by leucocyte count, gender and treatment and events after BMT are excluded. CR death, death in remission; BM + comb, relapse at bone marrow ± others.
Figure 5
Remission duration and relative risk at 5 years with standard error according to age group. Patients who died in remission are censored at death in remission. All analysis stratified by leucocyte count and sex.
Examination of outcome by ploidy group showed that patients with high-hyperdiploidy had a significantly better prognosis while near haploidy, hypodiploidy and pseudodiploidy were all associated with an increased risk of treatment failure. Table 6 gives the results for the cytogenetic variables in this set of patients. The only major difference in analysis of this subset of patients was that pre-pre-B appeared much less significant (stratified log-rank test: 2p = 0.03) and spleen enlargement became significant after stratification (2p = 0.006).
Cox proportional hazards models
Cox's proportional hazards models were used to determine if the identified prognostic factors accounted for the influence of age on disease progression. First, those factors (excluding age) that remained significant after stratification by WBC and gender (male = 0, female = 1) were included in a model. In order to account for as much of the variation as possible, the log of (WBC + 1) was used and Hb was treated as a continuous variable. The number of treatment blocks was also included. Then, once these factors had been allowed for, the significance of age was tested. Three models were fitted.
(1) All patients:
The initial model was based on 2034 patients without missing values and included treatment and the non-cytogenetic variables significant after stratification ( Table 5 ). The following variables were significant at the 5% level (most significant first): WBC, gender, Hb, BM blasts and pre-pre-B ALL. Age then entered the model as the most significant variable (P Ͻ 0.00001) rendering Hb and pre-pre-B ALL insignificant. In the final model (which included age group as well as age in years in order to make allowance for the possibility of a non-linear effect with age), treatment had a significant influence on disease free survival (P = 0.006). The initial model included the same variables as in (1) with the addition of spleen, t (9;22) and the significant ploidy groups in Table 6 . It was based on 1080 patients in whom all the variables had been recorded and the following were significant at the 5% level (most significant first): Ph+, WBC, gender, BM blasts, hypoploidy, haploidy, Hb and high hyperdiploidy. Again age entered the above model as the most significant variable (P Ͻ 0.00001) rendering Hb and high hyperdiploidy insignificant. In this model, Ph+ and hypodiploidy were associated with an approximate doubling in risk of failure and haploidy multiplied the risk by a factor of 4.7. Univariate and stratified analysis for the subset of patients in whom cytogenetics had been performed. a Only cases with cytogenetic result n = 1160.
(3) Omission of PhЈ positive patients: Since PhЈ positivity is strongly associated with poor survival, it may be thought of as a different type of leukaemia and would probably result in a change of treatment policy, the analyses were repeated with the exclusion of the PhЈ positive patients. In this subset of patients, lymph nodes, spleen and pseudodiploidy were not significant after stratification by WBC and gender and so were not included in the model. The final model, below, based on 1036 patients, was very similar to that in (2) (with the omission of t(9;22)) with haploidy associated with a 4.6 times increase in risk.
0.02 age + 0.21 age group + 0.28 log(WBC + 1) + −0.53 sex + 1.53 haploidy + 0.64 hypoploidy + −0.25 BM blasts
Discussion
Despite numerous separate reports of treatment outcome in both adult and paediatric ALL there have been few recent analyses involving a large cohort of patients receiving treatment across all similar age ranges: MRC UKALL X and XA have allowed these comparisons. The results of these two trials clearly illustrate the different distribution of biological subtypes between children and adults with lymphoblastic leukaemia but also show how, even after allowing for these differences, increasing age impacts on prognosis; event-free survival was significantly worse with increasing age. The trial was not designed to examine treatment after relapse, so that the observations about survival are not based on comparable treatments, but as expected there was a similar relationship between age and overall survival.
Selective entry of younger adults with ALL is a feature of 471 most therapeutic trials and this one was no exception. As shown in Table 1 , where the age-related incidence of ALL is calculated on the results of a national epidemiological survey with central haematological review, there is substantial underrepresentation of older patients in UKALL XA; as there was in the precursor UKALL IX where 80% of the patients were under 40. 6 It is possible that selective entry of older adults to UKALL XA has resulted in an over-estimate of survival chances in this age group. A review of all recent studies of adult ALL with more than 100 patients and follow-up of over 3 years showed that the median age for all patients in these series was 29. The overall remission rate was 74% and one third of patients was alive at 5 years. 12 By contrast a comprehensive analysis of all cases of ALL occurring in one region in the UK showed clearly that 30% of adult ALL occurs in the over-60s and the estimated long-term survival rate overall was probably more in the region of 20%. 13 This estimate concurs with that expressed in a recent review of ALL in adults by Copelan and McGuire 14 who expressed the view that no North American study has shown results superior to 20% cure.
A number of reasons contribute to the poor outcome for adults with ALL and some of these are illustrated in this study. These have recently been comprehensively reviewed 14 and may include: differences in the biology of the leukaemia, protocol design, compliance, and the increased toxicity of cytotoxic drugs with increasing age. MRC UKALL X and XA were large trials with a uniform design for both children and adults and afford a good opportunity for a critical assessment of some of these possible factors.
Examination of clinical features at presentation shows that once infants are excluded from analysis there was no clear relationship between age and presenting leucocyte count however, patients with very high white cell counts were more frequent among the 10-39 age group.
Immunophenotyping was not performed centrally and it was thus not possible to obtain a detailed subset analysis of B-and T-lineage precursors or to estimate the proportion of patients with myeloid antigen-positive leukaemia. The results of immunophenotyping showed, predictably, the relatively high incidence of T-ALL in the 10-40 age group and the childhood dominance of early pre-B or common ALL. Increasing age was associated with a higher incidence of pre-pre-B ALL. T-ALL has a poor prognosis in some paediatric studies 15, 16 but not others 17 and outcome may at least in part be related to the often high leucocyte count. There are conflicting reports about the prognostic significance of immunophenotype in adult ALL, with evidence from the German group that survival in pre-T lineage is poor but that the more mature phenotype has a better prognosis. 12 In this multivariate analysis T-ALL was only marginally associated with a worse prognosis after allowing for leucocyte count. However the adverse outcome associated with the pre-pre-B ALL phenotype retained significance until allowance was made for age.
Cytogenetic analysis identified both favourable and unfavourable factors and these were also age-related, except for haploidy and hypodiploidy. One quarter of children had high hyperdiploid ALL, a finding associated with a low leucocyte count and the common-ALL phenotype. 18 A biological explanation for this outcome has been provided by the finding that blasts from high hyperdiploid ALL selectively accumulate methotrexate polyglutamates 19 and are preferentially more sensitive to other cytotoxic drugs. 20 Methotrexate accumulation is a feature of B-lineage leukaemia 21 and blasts derived from this lineage from adults with ALL accumulate less methotrexate than those of children. 22 Preliminary analysis has shown that steroid resistance is increased in lymphoblasts from adults compared with children. 23 Expression of multidrug resistance associated membrane proteins, is associated in adult ALL with failure of response to remission induction and a higher relapse risk. 24 This evidence tends to support the concept that adult ALL is intrinsically less sensitive to chemotherapy, as presently used, possibly because the disease originates in drug-resistant stem cells with extensive self-renewal capacity. 25 The most important adverse cytogenetic finding was, as expected, the presence of the PhЈ chromosome. Whilst patients with t(4;11) had a poor prognosis, the numbers were small and this finding was invariably associated with a high leucocyte count. No other cytogenetic abnormality was associated with a high risk of treatment failure but the numbers of individual cases was small; in particular patients with t(1;19) did not have a higher risk of relapse; thus confirming other reports that more effective treatment may overcome the previously poor prognosis associated with this finding. 26 The incidence of PhЈ positive ALL, as shown in other studies, 27 steadily increased with age and was 19% in the over 40s. The influence of PhЈ ALL and of ploidy abnormalities became apparent once cytogenetics was added to the Cox model but even then age retained significance.
Is there evidence that treatment factors as well as host factors contribute to outcome? Remission induction is clearly less successful with increasing age, and the rate of death in remission, an indicator of treatment-related toxicity, increased with age, but we were unable to determine whether this could have been reduced by better supportive care.
The effect of centre size and outcome has been studied in childhood leukaemia 28 and in the context of bone marrow transplantation; 29 there is some evidence that a critical mass of patients is necessary to optimise outcome. However little attention has been paid to the effects of treatment centre, supportive care or protocol compliance in the treatment of adult acute leukaemia. Paediatric patients with leukaemia in the UK tend to have more centralised treatment than adults and the results of this trial showed stricter compliance in the paediatric arm than the adult arm. However, patients in the adult trial who deviated from protocol in general received more intensive treatment than they were randomised to have. Recent analysis from the American Children's Cancer Group shows that adults aged 16-21 years treated on CCG protocols had a 6-year event-free survival of 59% which was equivalent to that seen in children aged 10-15. 30 Similar results have been reported in 10-18 year olds treated at St Jude Children's Research Hospital. 31 These reports suggest that treatment results in adolescents and young adults may be improved by intensification of conventional therapy but it is not clear whether the improvement is due to the choice of protocol or institution. It has been suggested that inadequate drug delivery during post-remission therapy may contribute to treatment failure in adult ALL, 32 and there has been a recent plea for assessment of institutional performance and dose intensity. 33 Clearly alternative treatment strategies are needed for the management of lymphoblastic leukaemia in adults. Cytogenetic analysis or molecular diagnosis and immunophenotyping are essential in defining prognosis. It has recently become apparent that a frequent translocation giving rise to the TEL/AML1 disease product is associated with a favourable prognosis and is most commonly observed in younger children. Further studies will be required to determine what proportion of the impact of age is accounted for by this feature.
An explanation for the declining prospects with increasing age must be sought. We are not aware of studies of telomere length or of telomerase activity in ALL but these studies have been performed in normal leucocytes and in myeloid leukaemia. 34, 35 Loss of telomere length with increasing age may lead to genomic instability and cell death or the emergence of immortal clones with increased telomerase activity. Further studies should demand the deposition of material for genetic study to uncover the causes of the effect of age on outcome.
